ATX — Amplia Therapeutics Share Price
0.000.00%
Last trade - 00:00- AU$16.50m
- AU$12.00m
- AU$4.44m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.29 | ||
| Price to Tang. Book | 3.41 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.88 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -49.1% | ||
| Return on Equity | -44.96% | ||
| Operating Margin | -185.55% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.03 | 1.53 | 1.98 | 1.15 | 4.44 | n/a | n/a | 144.81% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The Company's pipeline includes narmafotinib (AMP945) and AMP886. narmafotinib is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company's second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.
Directors
- Warwick Tong CHM
- John Lambert CEO
- Hamish George CFO
- Mark Devlin CSO
- Janette Dixon VBD
- Margaret Rhoades OTH
- Ken Tucker OTH
- Andrew Cooke SEC
- Christopher Burns DRC
- Jane Bell NED
- Robert Peach NED (62)
- Last Annual
- March 31st, 2024
- Last Interim
- September 30th, 2024
- Incorporated
- October 11th, 2013
- Public Since
- December 23rd, 2013
- No. of Employees
- 1
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 317,402,701
- Address
- Level 17, 350 Queen Street, MELBOURNE, 3000
- Web
- https://www.ampliatx.com/site/content/
- Phone
- +61 391231140
- Auditors
- Grant Thornton Audit Pty Ltd
Upcoming Events for ATX
Amplia Therapeutics Ltd Annual Shareholders Meeting
Similar to ATX
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Anteotech
Australian Stock Exchange - SEATS
FAQ
What is the Amplia Therapeutics share price?
As of Today at 19:15 UTC, shares in Amplia Therapeutics are trading at AU$0.05. This share price information is delayed by 15 minutes.
How has the Amplia Therapeutics share price performed this year?
Shares in Amplia Therapeutics last closed at AU$0.05 and the price had moved by -10.51% over the past 365 days. In terms of relative price strength the Amplia Therapeutics share price has underperformed the ASX All Ordinaries Index by -11.88% over the past year.
What are the analyst and broker recommendations for Amplia Therapeutics?
There is no consensus recommendation for this security.
Find out moreWhat is the Amplia Therapeutics dividend yield?
Amplia Therapeutics does not currently pay a dividend.
Does Amplia Therapeutics pay a dividend?
Amplia Therapeutics does not currently pay a dividend.
When does Amplia Therapeutics next pay dividends?
Amplia Therapeutics does not currently pay a dividend.
How do I buy Amplia Therapeutics shares?
To buy shares in Amplia Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Amplia Therapeutics?
As of the previous close price of AU$0.05, shares in Amplia Therapeutics had a market capitalisation of AU$16.50m.
Where are Amplia Therapeutics shares listed?
Here are the trading details for Amplia Therapeutics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: ATX
What kind of share is Amplia Therapeutics?
Based on an overall assessment of its quality, value and momentum Amplia Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Amplia Therapeutics share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Amplia Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Amplia Therapeutics. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -63.29%.
As of the last closing price of AU$0.05, shares in Amplia Therapeutics were trading -45.25% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Amplia Therapeutics PE Ratio?
The Amplia Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Amplia Therapeutics?
Amplia Therapeutics' management team is headed by:
- Warwick Tong - CHM
- John Lambert - CEO
- Hamish George - CFO
- Mark Devlin - CSO
- Janette Dixon - VBD
- Margaret Rhoades - OTH
- Ken Tucker - OTH
- Andrew Cooke - SEC
- Christopher Burns - DRC
- Jane Bell - NED
- Robert Peach - NED